Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Differential Clinical Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies.
Yang H, Lu X, Peng Q, Jiang W, Shi J, Zhang Y, Chen H, Wang G. Yang H, et al. Among authors: jiang w. Arthritis Rheumatol. 2018 Aug;70(8):1288-1297. doi: 10.1002/art.40491. Epub 2018 Jun 27. Arthritis Rheumatol. 2018. PMID: 29534337 Free article.
OBJECTIVE: To investigate the associations between anti-nuclear matrix protein 2 (anti-NXP-2) autoantibody levels and disease activity as well as calcinosis severity in patients with idiopathic inflammatory myopathies (IIMs). METHODS: Serum levels of anti-NXP-2 auto …
OBJECTIVE: To investigate the associations between anti-nuclear matrix protein 2 (anti-NXP-2) autoantibody levels and disease activity as we …
The role of interferons type I, II and III in myositis: A review.
Bolko L, Jiang W, Tawara N, Landon-Cardinal O, Anquetil C, Benveniste O, Allenbach Y. Bolko L, et al. Among authors: jiang w. Brain Pathol. 2021 May;31(3):e12955. doi: 10.1111/bpa.12955. Brain Pathol. 2021. PMID: 34043262 Free PMC article.
The classification of idiopathic inflammatory myopathies (IIM) is based on clinical, serological and histological criteria. ...Moreover, the pathophysiological mechanisms are distinct between each myositis subsets. Recently, interferon (IFN) pathways have bee …
The classification of idiopathic inflammatory myopathies (IIM) is based on clinical, serological and histological criteria. .. …
The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study.
Li S, Li W, Jiang W, He L, Peng Q, Wang G, Lu X. Li S, et al. Among authors: jiang w. Front Pharmacol. 2021 Mar 16;12:635654. doi: 10.3389/fphar.2021.635654. eCollection 2021. Front Pharmacol. 2021. PMID: 33815117 Free PMC article.
Objective: To evaluate the efficacy of tocilizumab (TCZ) in adult patients with refractory immune-mediated necrotizing myopathies (IMNMs) and investigate possible predictive biomarkers of the response to treatment with TCZ. ...Seven (63.6%) of these patients achieved clini …
Objective: To evaluate the efficacy of tocilizumab (TCZ) in adult patients with refractory immune-mediated necrotizing myopathies (IM …